In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis

Carlo Viscomi, Emanuela Bottani, Gabriele Civiletto, Raffaele Cerutti, Maurizio Moggio, Gigliola Fagiolari, Eric A. Schon, Costanza Lamperti, Massimo Zeviani

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Increased mitochondrial biogenesis by activation of PPAR- or AMPK/PGC-1α-dependent homeostatic pathways has been proposed as a treatment for mitochondrial disease. We tested this hypothesis on three recombinant mouse models characterized by defective cytochrome c-oxidase (COX) activity: a knockout (KO) mouse for Surf1, a knockout/knockin mouse for Sco2, and a muscle-restricted KO mouse for Cox15. First, we demonstrated that double-recombinant animals overexpressing PGC-1α in skeletal muscle on a Surf1 KO background showed robust induction of mitochondrial biogenesis and increase of mitochondrial respiratory chain activities, including COX. No such effect was obtained by treating both Surf1-/- and Cox15-/- mice with the pan-PPAR agonist bezafibrate, which instead showed adverse effects in either model. Contrariwise, treatment with the AMPK agonist AICAR led to partial correction of COX deficiency in all three models, and, importantly, significant motor improvement up to normal in the Sco2KO/KI mouse. These results open new perspectives for therapy of mitochondrial disease.

Original languageEnglish
Pages (from-to)80-90
Number of pages11
JournalCell Metabolism
Volume14
Issue number1
DOIs
Publication statusPublished - Jul 6 2011

Fingerprint

AMP-Activated Protein Kinases
Knockout Mice
Mitochondrial Diseases
Oxidoreductases
Peroxisome Proliferator-Activated Receptors
Organelle Biogenesis
Bezafibrate
Electron Transport Complex IV
Electron Transport
Skeletal Muscle
Muscles
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Cite this

Viscomi, C., Bottani, E., Civiletto, G., Cerutti, R., Moggio, M., Fagiolari, G., ... Zeviani, M. (2011). In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metabolism, 14(1), 80-90. https://doi.org/10.1016/j.cmet.2011.04.011

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. / Viscomi, Carlo; Bottani, Emanuela; Civiletto, Gabriele; Cerutti, Raffaele; Moggio, Maurizio; Fagiolari, Gigliola; Schon, Eric A.; Lamperti, Costanza; Zeviani, Massimo.

In: Cell Metabolism, Vol. 14, No. 1, 06.07.2011, p. 80-90.

Research output: Contribution to journalArticle

Viscomi, C, Bottani, E, Civiletto, G, Cerutti, R, Moggio, M, Fagiolari, G, Schon, EA, Lamperti, C & Zeviani, M 2011, 'In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis', Cell Metabolism, vol. 14, no. 1, pp. 80-90. https://doi.org/10.1016/j.cmet.2011.04.011
Viscomi, Carlo ; Bottani, Emanuela ; Civiletto, Gabriele ; Cerutti, Raffaele ; Moggio, Maurizio ; Fagiolari, Gigliola ; Schon, Eric A. ; Lamperti, Costanza ; Zeviani, Massimo. / In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. In: Cell Metabolism. 2011 ; Vol. 14, No. 1. pp. 80-90.
@article{bfb6ce79ab4541e9a3f222ae5e1dcca0,
title = "In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis",
abstract = "Increased mitochondrial biogenesis by activation of PPAR- or AMPK/PGC-1α-dependent homeostatic pathways has been proposed as a treatment for mitochondrial disease. We tested this hypothesis on three recombinant mouse models characterized by defective cytochrome c-oxidase (COX) activity: a knockout (KO) mouse for Surf1, a knockout/knockin mouse for Sco2, and a muscle-restricted KO mouse for Cox15. First, we demonstrated that double-recombinant animals overexpressing PGC-1α in skeletal muscle on a Surf1 KO background showed robust induction of mitochondrial biogenesis and increase of mitochondrial respiratory chain activities, including COX. No such effect was obtained by treating both Surf1-/- and Cox15-/- mice with the pan-PPAR agonist bezafibrate, which instead showed adverse effects in either model. Contrariwise, treatment with the AMPK agonist AICAR led to partial correction of COX deficiency in all three models, and, importantly, significant motor improvement up to normal in the Sco2KO/KI mouse. These results open new perspectives for therapy of mitochondrial disease.",
author = "Carlo Viscomi and Emanuela Bottani and Gabriele Civiletto and Raffaele Cerutti and Maurizio Moggio and Gigliola Fagiolari and Schon, {Eric A.} and Costanza Lamperti and Massimo Zeviani",
year = "2011",
month = "7",
day = "6",
doi = "10.1016/j.cmet.2011.04.011",
language = "English",
volume = "14",
pages = "80--90",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis

AU - Viscomi, Carlo

AU - Bottani, Emanuela

AU - Civiletto, Gabriele

AU - Cerutti, Raffaele

AU - Moggio, Maurizio

AU - Fagiolari, Gigliola

AU - Schon, Eric A.

AU - Lamperti, Costanza

AU - Zeviani, Massimo

PY - 2011/7/6

Y1 - 2011/7/6

N2 - Increased mitochondrial biogenesis by activation of PPAR- or AMPK/PGC-1α-dependent homeostatic pathways has been proposed as a treatment for mitochondrial disease. We tested this hypothesis on three recombinant mouse models characterized by defective cytochrome c-oxidase (COX) activity: a knockout (KO) mouse for Surf1, a knockout/knockin mouse for Sco2, and a muscle-restricted KO mouse for Cox15. First, we demonstrated that double-recombinant animals overexpressing PGC-1α in skeletal muscle on a Surf1 KO background showed robust induction of mitochondrial biogenesis and increase of mitochondrial respiratory chain activities, including COX. No such effect was obtained by treating both Surf1-/- and Cox15-/- mice with the pan-PPAR agonist bezafibrate, which instead showed adverse effects in either model. Contrariwise, treatment with the AMPK agonist AICAR led to partial correction of COX deficiency in all three models, and, importantly, significant motor improvement up to normal in the Sco2KO/KI mouse. These results open new perspectives for therapy of mitochondrial disease.

AB - Increased mitochondrial biogenesis by activation of PPAR- or AMPK/PGC-1α-dependent homeostatic pathways has been proposed as a treatment for mitochondrial disease. We tested this hypothesis on three recombinant mouse models characterized by defective cytochrome c-oxidase (COX) activity: a knockout (KO) mouse for Surf1, a knockout/knockin mouse for Sco2, and a muscle-restricted KO mouse for Cox15. First, we demonstrated that double-recombinant animals overexpressing PGC-1α in skeletal muscle on a Surf1 KO background showed robust induction of mitochondrial biogenesis and increase of mitochondrial respiratory chain activities, including COX. No such effect was obtained by treating both Surf1-/- and Cox15-/- mice with the pan-PPAR agonist bezafibrate, which instead showed adverse effects in either model. Contrariwise, treatment with the AMPK agonist AICAR led to partial correction of COX deficiency in all three models, and, importantly, significant motor improvement up to normal in the Sco2KO/KI mouse. These results open new perspectives for therapy of mitochondrial disease.

UR - http://www.scopus.com/inward/record.url?scp=79959314684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959314684&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2011.04.011

DO - 10.1016/j.cmet.2011.04.011

M3 - Article

C2 - 21723506

AN - SCOPUS:79959314684

VL - 14

SP - 80

EP - 90

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 1

ER -